Maravai LifeSciences (MRVI) Q1 2026 earnings summary

Executive summary

• Q1 2026 revenue reached $65.8 million, up 41% year-over-year, with base business growth of 10% excluding COVID-related CleanCap revenue; TriLink drove growth with 15% base revenue increase, while Cygnus remained stable with 1% growth and strong demand in North America and EMEA.

• Adjusted EBITDA improved to $20.3 million, a year-over-year increase of over $30 million, and positive free cash flow of $4.2 million was generated, reflecting higher revenue, favorable mix, and cost discipline.

• Net loss narrowed to $6.4 million from $52.9 million in the prior year quarter; adjusted EPS was $0.01, up from a loss of $0.08.

• Structural improvements and operational excellence initiatives are translating into sustained performance and margin expansion.

• Strategic focus on commercial execution, operational excellence, and innovation is yielding results.

Financial highlights

• Adjusted gross margin was 65.3%, up from 41.0% year-over-year; gross profit margin rose to 51.2% from 16.5% year-over-year, reflecting favorable product mix and cost reductions.

• GAAP net loss before non-controlling interest was $6.4 million, a significant improvement from $52.9 million loss in Q1 2025; net loss attributable to the company was $3.7 million.

• Adjusted EBITDA improved by over $30 million year-over-year to $20.3 million.

• Ended the quarter with $165.9 million in cash and $242.9 million in long-term debt after a $50 million voluntary debt repayment.

• Depreciation and amortization was $11.4 million; net interest expense $3.9 million; stock-based compensation $6.7 million.

Outlook and guidance

• Full-year revenue guidance raised to $205–$215 million, representing 10–16% growth over 2025.

• Full-year adjusted EBITDA guidance raised to $30–$32 million, an improvement of $61–$63 million year-over-year.

• Management expects Q1 2026 to be the highest revenue quarter of the year due to the non-recurring CleanCap order; no further high-volume CleanCap orders for commercial COVID-19 vaccine programs are anticipated for the remainder of 2026.

• TriLink expected to grow in the high teens, driven by GMP consumables and discovery recovery; Cygnus expected to see low to mid-single digit growth.

• Positive free cash flow expected for the remainder of 2026.